Vanguard Capital Management
MYGN icon

Vanguard Capital Management’s Myriad Genetics MYGN Stock Holding History

Vanguard Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
4,081,376
+156,851
+4% +$712K ﹤0.01% 2363
2026
Q1 		$17.7M Buy
+3,924,525
New +$20.4M ﹤0.01% 2414

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's MYGN Position: Q2 2026 in Review

Vanguard Capital Management increased its Myriad Genetics (MYGN) stake by 4% in Q2 2026, buying an estimated $712K and bringing the position to 4,081,376 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Vanguard Capital Management first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Vanguard Capital Management held 4,081,376 shares of Myriad Genetics worth $23.3M as of Q2 2026.
  • Vanguard Capital Management bought 156,851 Myriad Genetics shares in Q2 2026, an estimated $712K.
  • Myriad Genetics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2363 holding.
  • Vanguard Capital Management first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.